Chlorpromazine (CPZ), a dopamine D2 receptor antagonist, is able to cross the cell membrane and bind to FKBP-12, inhibiting the mTOR pathway, one of the most frequent points of dysregulation in cancer (Supplementary Table S3). This evidence concerns the gene DRD2 and cancer.